Lifeboat Foundation

The ability to modify multiple genetic elements simultaneously would help to elucidate and control the gene interactions and networks underlying complex cellular functions. However, current genome engineering technologies are limited in both the number and the type of perturbations that can be performed simultaneously. Here, we demonstrate that both Cas12a and a clustered regularly interspaced short palindromic repeat (CRISPR) array can be encoded in a single transcript by adding a stabilizer tertiary RNA structure. By leveraging this system, we illustrate constitutive, conditional, inducible, orthogonal and multiplexed genome engineering of endogenous targets using up to 25 individual CRISPR RNAs delivered on a single plasmid. Our method provides a powerful platform to investigate and orchestrate the sophisticated genetic programs underlying complex cell behaviors.

A California “human biohacking” bill calls for warnings on do-it-yourself genetic-engineering kits.

Bioethicists hope a national committee will help close loopholes in the country’s biomedical ethics regulations.

Scientists agree that CRISPR holds great promise in giving researchers unprecedented power to snip out abnormal stretches of DNA, But there are still significant questions about how safe and effective CRISPR gene editing will be once it’s unleashed in the human body. CRISPR works well enough in the lab, in a dish of human cells, but as with any technology, there are glitches. Some studies have shown that the gene editing goes awry once in a while, splicing incorrect places in the genome. Then there is the bigger question of what longer term, unanticipated effects man-made edits to the human genome might have… (READ MORE)

Continue reading “CRISPR Gene Editing Is Being Tested In Human Patients And Scientists Admit They Do Not Know ‘What The Long-Term Effects Of Man-Made Edits To The Human Genome Might Have’” »

Ira Pastor, ideaXme longevity and aging Ambassador and Founder of Bioquark interviews Bill Faloon, Director and Co-Founder, Life Extension Foundation and Founder of The Church Of Perpetual Life.

Ira Pastor Comments:

Continue reading “Bill Faloon: A Life Long Quest To Reverse Human Aging!” »

The trial is just one of a few underway to test the powerful CRISPR technology around the world. One of the most promising, for example, is studying whether gene editing can treat, and effectively cure, blood disorders such as beta thalassemia and sickle cell anemia.

In beta thalassemia, the hemoglobin part of red blood cells, which is supposed to pick up oxygen from the lungs and distribute it to the cells in the rest of the body, doesn’t work properly. Patients need to be transfused with donors blood regularly, and even with these transfusions, complications can occur if the dose isn’t right and iron levels in the blood cells spike, which can lead to organ damage and even death. In sickle cell disease, a mutation in the gene that makes hemoglobin causes the red blood cells to collapse into a sickle shape, which makes it more difficult for the cells to flow smoothly through the body’s arteries and veins. Blockages caused by the misshapen blood cells can lead to severe pain and strokes.

The biotech company CRISPR Therapeutics, founded by one of the technology’s co-developers, has engineered a solution to treat both conditions that relies on genetic modifications connected to the production of fetal hemoglobin. Normally fetal hemoglobin, which provides the developing fetus with oxygen via the blood while in utero, is shut off about six months after birth, and genes for adult hemoglobin are turned on. While it’s not clear why adult hemoglobin replaces the fetal version, researchers say that they have not seen any significant differences between the two types when it comes to the ability to transport oxygen to the body’s cells. However, since the genes for adult hemoglobin don’t produce healthy red blood cells in people with beta thalassemia and sickle cell disease, one treatment strategy is to introduce genetic changes that turn on fetal hemoglobin again.

(repeat) Are you ready to defer all your personal decision-making to machines? Polls show that most Americans are uneasy about the unchecked growth of artificial intelligence. The possible misuse of genetic engineering also makes us anxious. We all have a stake in the responsible development of science and technology, but fortunately, science fiction films can help.

The movies Ex Machina and Jurassic Park suggest where A.I. and unfettered gene-tinkering could lead. But even less popular sci-fi movies can help us imagine unsettling scenarios regarding over-population, smart drugs, and human cloning.

And not all tales are grim. The 1951 film, The Man in the White Suit, weaves a humorous story of materials science run amok.

Lux Capital, a New York-based venture capital firm, has raised more than $1 billion across two new funds to back companies on “the cutting edge of science.” The firm raised $500 million for its sixth flagship early-stage fund and another $550 million for an opportunity fund focused on growth-stage investments. Limited partners include global foundations, university endowments, and tech billionaires.

Lux also announced a new hire: Deena Shakir, formerly of GV (Google Ventures), has joined as an investment partner.

To the regular person, Lux’s investments are considered moonshot. The firm has backed entrepreneurs that are working on everything from neurostimulation to nuclear energy to synthetic biology. During my last interview with co-founder and managing partner Josh Wolfe, I actually called one of his portfolio companies “freaking crazy.”